I am a
Home I AM A Search Login

Papers of the Week

2021 Jul-Aug 01

J Clin Psychopharmacol



A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.


Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, Chowdhry F, Cutler AJ, Jones N J, L Findling R, Schwabe S
J Clin Psychopharmacol. 2021 Jul-Aug 01; 41(4):370-380.
PMID: 34181360.


This phase 3 clinical trial evaluated the efficacy and safety of viloxazine extended-release capsules (VLX-ER) as a monotherapy for attention-deficit/hyperactivity disorder (ADHD) in adolescents (12-17 years).